메뉴 건너뛰기




Volumn 122, Issue 9, 2008, Pages 2142-2147

Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate

Author keywords

Antitumor; Breast cancer; Prodrug; Raloxifene

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PRODRUG; RALOXIFENE; RALOXIFENE DIPHOSPHATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARCINOGEN; DRUG DERIVATIVE; ORGANOPHOSPHATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

EID: 40749139106     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23362     Document Type: Article
Times cited : (8)

References (29)
  • 1
    • 0027172047 scopus 로고
    • A current view of tamoxifen for the treatment and prevention of breast cancer
    • Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993;110:507-17.
    • (1993) Br J Pharmacol , vol.110 , pp. 507-517
    • Jordan, V.C.1
  • 3
    • 0021960977 scopus 로고
    • Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens
    • Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
    • (1985) Cancer Treat Rep , vol.69 , pp. 237-238
    • Killackey, M.A.1    Hakes, T.B.2    Pierce, V.K.3
  • 6
    • 3042653655 scopus 로고    scopus 로고
    • Genotoxic mechanism of tamoxifen in developing endometrial cancer
    • Kim SY, Suzuki N, Laxmi YRS, Shibutani S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev 2004;36:199-218.
    • (2004) Drug Metab Rev , vol.36 , pp. 199-218
    • Kim, S.Y.1    Suzuki, N.2    Laxmi, Y.R.S.3    Shibutani, S.4
  • 7
    • 0034989609 scopus 로고    scopus 로고
    • Understanding the genotoxicity of tamoxifen?
    • Phillips DH. Understanding the genotoxicity of tamoxifen? Carcinogenesis 2001;22:839-49.
    • (2001) Carcinogenesis , vol.22 , pp. 839-849
    • Phillips, D.H.1
  • 8
    • 0036347450 scopus 로고    scopus 로고
    • The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial
    • Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 2002;3:153-9.
    • (2002) Clin Breast Cancer , vol.3 , pp. 153-159
    • Vogel, V.G.1    Costantino, J.P.2    Wickerham, D.L.3    Cronin, W.M.4    Wolmark, N.5
  • 12
    • 77951580891 scopus 로고    scopus 로고
    • Available at, Accessed September 14, 2007
    • FDA: FDA approves new uses for Evista. Available at http://www.fda.gov/ bbs/topics/NEWS/2007/NEW01698.html. Accessed September 14, 2007.
    • FDA approves new uses for Evista
  • 13
    • 0036266936 scopus 로고    scopus 로고
    • Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance
    • Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 2002;30:694-700.
    • (2002) Drug Metab Dispos , vol.30 , pp. 694-700
    • Kemp, D.C.1    Fan, P.W.2    Stevens, J.C.3
  • 14
    • 18844431909 scopus 로고    scopus 로고
    • Species- and disposition model-dependent metabolism of raloxifene in gut and liver: Role of UGT1A10
    • Jeong EJ, Liu Y, Lin H, Hu M. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 2005;33:785-94.
    • (2005) Drug Metab Dispos , vol.33 , pp. 785-794
    • Jeong, E.J.1    Liu, Y.2    Lin, H.3    Hu, M.4
  • 16
    • 0023229345 scopus 로고
    • Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
    • Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4.
    • (1987) Cancer Res , vol.47 , pp. 4020-4024
    • Gottardis, M.M.1    Jordan, V.C.2
  • 18
    • 41149085588 scopus 로고    scopus 로고
    • Chen Z, Gao Q, Yuan L, Yuan L, Tang Z, Wu Z. Application of novel benzothiophene derivatives in treating postmenstrual syndrome and other estrogen-related diseases. Faming Zhuanli Shenqing Gongkai Shuomingshu (2002), 20pp. CN 1370533 A 20020925 (written in Chinese). Application: CN 2001-104434 20010227. CAN 139:271010.
    • Chen Z, Gao Q, Yuan L, Yuan L, Tang Z, Wu Z. Application of novel benzothiophene derivatives in treating postmenstrual syndrome and other estrogen-related diseases. Faming Zhuanli Shenqing Gongkai Shuomingshu (2002), 20pp. CN 1370533 A 20020925 (written in Chinese). Application: CN 2001-104434 20010227. CAN 139:271010.
  • 19
    • 41149142456 scopus 로고    scopus 로고
    • Asao T, Takeda S, Sugimoto Y, Toko T, Yamada Y, Ogawa K, Unemi N. Preparation of butenylphenyl phosphates as drugs for mammary cancer and anovulatory sterility. PCT Int. Appl. 44 pp.WO 8707609 A (1987).
    • Asao T, Takeda S, Sugimoto Y, Toko T, Yamada Y, Ogawa K, Unemi N. Preparation of butenylphenyl phosphates as drugs for mammary cancer and anovulatory sterility. PCT Int. Appl. 44 pp.WO 8707609 A (1987).
  • 20
    • 0035023196 scopus 로고    scopus 로고
    • Differential SERM activation of the estrogen receptors (ERα and ERβ) at AP-1 sites
    • Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERα and ERβ) at AP-1 sites. Chem Biol 2001;8:427-36.
    • (2001) Chem Biol , vol.8 , pp. 427-436
    • Weatherman, R.V.1    Clegg, N.J.2    Scanlan, T.S.3
  • 21
    • 19944427846 scopus 로고    scopus 로고
    • TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect
    • Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, Buzdar AU, Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect. Clin Cancer Res 2005;11:315-22.
    • (2005) Clin Cancer Res , vol.11 , pp. 315-322
    • Yamamoto, Y.1    Shibata, J.2    Yonekura, K.3    Sato, K.4    Hashimoto, A.5    Aoyagi, Y.6    Wierzba, K.7    Yano, S.8    Asao, T.9    Buzdar, A.U.10    Terada, T.11
  • 23
    • 27544464442 scopus 로고    scopus 로고
    • Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of α-hydroxytamoxifen in rat and human livers
    • Kim SY, Laxmi YRS, Suzuki N, Ogura K, Watabe T, Duffel MW, Shibutani S. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of α-hydroxytamoxifen in rat and human livers. Drug Metab Dispos 2005;33:1673-8.
    • (2005) Drug Metab Dispos , vol.33 , pp. 1673-1678
    • Kim, S.Y.1    Laxmi, Y.R.S.2    Suzuki, N.3    Ogura, K.4    Watabe, T.5    Duffel, M.W.6    Shibutani, S.7
  • 24
    • 0017184389 scopus 로고
    • A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
    • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
    • (1976) Anal Biochem , vol.72 , pp. 248-254
    • Bradford, M.M.1
  • 25
    • 0020582094 scopus 로고
    • Effects of a new antiestrogen. Keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on. LH and prolactin levels
    • Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen. Keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on. LH and prolactin levels. Life Sci 1983;32:2869-75.
    • (1983) Life Sci , vol.32 , pp. 2869-2875
    • Clemens, J.A.1    Bennett, D.R.2    Black, L.J.3    Jones, C.D.4
  • 27
    • 0042143281 scopus 로고    scopus 로고
    • Targeted prodrug design to optimize drug delivery
    • article E6
    • Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2002;2:article E6.
    • (2002) AAPS PharmSci , Issue.2
    • Han, H.K.1    Amidon, G.L.2
  • 29
    • 33745876266 scopus 로고    scopus 로고
    • Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
    • Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Komitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
    • (2006) N Engl J Med , vol.355 , pp. 125-137
    • Barrett-Connor, E.1    Mosca, L.2    Collins, P.3    Geiger, M.J.4    Grady, D.5    Komitzer, M.6    McNabb, M.A.7    Wenger, N.K.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.